April 22nd 2024
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Expert Reflects on Exciting Year of AML Approvals and Looks Ahead to Active Areas of Research
February 28th 2018The treatment paradigm of acute myeloid leukemia has not changed much in the last several decades, but with 4 new drugs approved by the FDA within the span of a few months, 2017 easily became the most promising year yet for the treatment of AML.
Read More
A Study of Duvelisib vs Ofatumumab in Relapsed/Refractory CLL
February 28th 2018Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses the phase III DUO trial, a randomized comparison of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia.
Watch
Umbralisib Shows Encouraging Early Activity in CLL and Lymphoma
February 23rd 2018According to phase I findings published in <em>The Lancet Oncology,</em> an objective response rate of 37% was induced in patients with relapsed/refractory lymphoma or chronic lymphocytic leukemia treated with the PI3K-delta inhibitor umbralisib.
Read More
Ivosidenib Granted Priority Review Designation by FDA for IDH1+ AML
February 15th 2018Based on findings from a phase I trial presented at the 2017 ASH Annual Meeting, ivosidenib (AG-120) has been granted a priority review designation by the FDA for the treatment of patients with relapsed/refractory <em>IDH1</em>-mutant acute myeloid leukemia.
Read More
Duvelisib Submitted for FDA Approval in CLL, Follicular Lymphoma
February 7th 2018Based on supporting data from the phase III DUO trial and the phase II DYNAMO study, duvelisib has been submitted to the FDA for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma.
Read More
A Phase II Study of Ibrutinib Plus FCR as Frontline Therapy in Younger CLL Patients
February 7th 2018Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a multicenter study of ibrutinib (Imbruvica) plus FCR as a frontline therapy for younger patients with chronic lymphocytic leukemia (CLL). <br />
Watch
Arsenic Trioxide Approved by FDA for Promyelocytic Leukemia
January 17th 2018Arsenic trioxide (Trisenox) has been approved by the FDA in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or <em>PML-RARA</em> gene expression.
Read More
Ivosidenib Submitted for FDA Approval in IDH1+ AML
December 27th 2017Based on results of a phase I trial presented at the 2017 ASH Annual Meeting, a new drug applicaton for ivosidenib has been submitted for FDA approval for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.
Read More
Nilotinib Label for CML Updated by FDA With Discontinuation Provision
December 26th 2017The label for nilotinib (Tasigna) has been updated by the FDA with a provision stating patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) who have received the BCR-ABL tyrosine kinase inhibitor could be eligible to stop treatment after having recieved for at least 3 years and having achieved the specific predetermined criteria.<br /> <br />
Read More
Ibrutinib Plus Chemoimmunotherapy Demonstrates Promising Frontline Results in CLL
December 19th 2017In patients with chronic lymphocytic leukemia (CLL), the addition of ibrutinib to standard frontline chemoimmunotherapy induced negative minimum residual disease (MRD) status in bone marrow for 83% of patients, according to results from a preliminary clinical study presented at the 2017 ASH Annual Meeting.
Read More
DFS Maintained in HR+ Breast Cancer With Fewer Years of AI Therapy
December 8th 2017Disease-free survival is maintained in women with postmenopausal hormone receptor-positive breast cancer treated with aromatase inhibitors, even when the treatment is only given for 2 years in comparison with the standard 5 years of additional aromatase inhibitor therapy, according to findings from the phase III ABCSG-16 trial presented at the 2017 San Antonio Breast Cancer Symposium.
Read More
Venetoclax for the Treatment of Elderly Patients With CLL
December 7th 2017Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses venetoclax (Venclexta) for the treatment of elderly patients with chronic lymphocytic leukemia (CLL).
Watch
Optimal Treatment Sequencing for Patients With CLL
December 5th 2017Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses optimal treatment sequencing for patients with chronic lymphocytic leukemia (CLL).
Watch
Savoldo Receives Grant for Immunotherapy Research from The Leukemia & Lymphoma Society
December 1st 2017The Leukemia & Lymphoma Society (LLS) has awarded Barbara Savoldo, MD, PhD, with a $600,000, 3-year grant in support of her promising research into a CAR T-cell treatment with a “safety switch” that could alleviate potential side effects for patients with acute lymphoblastic leukemia being treated with the immunotherapy.
Read More
James R. Downing to Receive ASH's 2017 E. Donnall Thomas Lecture Prize
November 28th 2017The American Society of Hematology has announced that James R. Downing, MD, of St. Jude Children’s Research Hospital will be awarded the 2017 E. Donnall Thomas Lecture and Prize for his discoveries related to the hematopathology and molecular biology of childhood leukemia.
Read More
How Ibrutinib Has Transformed the Treatment Paradigm of CLL
September 21st 2017Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses how ibrutinib has transformed the treatment landscape of chronic lymphocytic leukemia.
Watch
Patients With High-Risk, Refractory CLL Achieve High Response Rate With CAR T-Cell Therapy
September 21st 2017Results of a small, single-arm study reported at the 2017 Society of Hematologic Oncology meeting showed patients with refractory chronic lymphocytic leukemia achieved a high response rate with CD19-targeted CAR T-cell therapy.
Read More
Midostaurin Granted EU Approval for AML, Advanced Systemic Mastocytosis
September 20th 2017Midostaurin has received approval from the European Commission as a treatment for adults with newly diagnosed <em>FLT3</em>-positive acute myeloid leukemia and advanced systemic mastocytosis, including aggressive systemic mastocytosis, SM with associated hematological neoplasm, and mast cell leukemia.
Read More
Building on the Success of BCL-2 Inhibition in AML
September 18th 2017Understanding of the role of BCL-2 in acute myeloid leukemia (AML) continues to evolve, even as BCL-2–targeted therapy improves outcomes in the disease, AML specialist Daniel Pollyea, MD, MS said at the 2017 Society of Hematologic Oncology Annual Meeting in Houston, Texas.
Read More
Bosutinib Distinguishes Itself as Potential Option for Newly-Diagnosed CML
September 16th 2017Initial results from a phase III trial indicated that patients with newly diagnosed chronic myeloid leukemia treated with bosutinib (Bosulif) achieved response faster than patients treated with imatinib (Gleevec).
Read More
Challenges, Needs to Improve Treatment of Pediatric ALL
September 15th 2017Efforts to improve outcomes in pediatric acute lymphoblastic leukemia should follow leads provided by next-generation sequencing and appropriate use of minimal residual disease criteria, a pediatric hematologist said at the 2017 Society of Hematology Oncology Annual Meeting in Houston.
Read More
FDA Gives OK to First CAR T-Cell Therapy as Tisagenlecleucel Approved for ALL
August 30th 2017A historic approval of the first chimeric antigen receptor (CAR) T-cell therapy has been issued by the FDA, authorizing the use of tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.
Read More
Study Finds Hospice Not Being Used Optimally for End-of-Life AML Care
August 28th 2017Results from a recent retrospective study published in the<em> Journal of Clinical Oncology</em><sup> </sup>revealed hospice enrollment is low and use of aggressive treatment is high for elderly patients with acute myeloid leukemia.
Read More
Crenolanib Shows Promise as TKIs Move to Forefront of AML Treatment, Expert Says
August 28th 2017Eunice Wang, MD, discusses a study examining the biology of newly diagnosed patients with <em>FLT3</em>-positive acute myeloid leukemia who achieved a response to the FLT3 TKI crenolanib combined with chemotherapy.
Read More